PPT-COAPT A Randomized Trial of Transcatheter Mitral Valve Leaflet Approximation in Patients

Gregg W Stone MD On behalf of Michael Mack William Abraham JoAnn Lindenfeld and the COAPT Investigators Gregg W Stone MD Consulting fees from Neovasc Valfix Gore Equityoptions in Ancora. 1 November 11 2013 COAPT protocol approved by FDA July 27 2012 Trial Design Key Inclusion Criteria Leaflet anatomy which may preclude MitraClip implantation proper MitraClip positioning on the leaflets or sufficient MR reduction by the MitraClip MV o TSXV: NVC. Alexei Marko, CEO. Chris Clark, CFO. October 2013. Forward-Looking Statements. Statements contained herein that are not based on historical or current fact, including without limitation statements containing the words “anticipates,” “believes,” “may,” “continues,” “estimates,” “expects,” and “will” and words of similar import, constitute “forward-looking statements” within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, events or developments to be materially different from any future results, events or developments expressed or implied by such forward-looking statements. Such factors include, among others, the following: general economic and business conditions, both nationally and in the regions in which the Company operates; technology changes; competition; changes in business strategy or development plans; the ability to attract and retain qualified personnel; existing governmental regulations and changes in, or the failure to comply with, governmental regulations; liability and other claims asserted against the Company; and other factors referenced in the Company’s filings with Canadian securities regulators. Given these uncertainties, readers are cautioned not to place undue reliance on such forward-looking statements. The Company does not assume the obligation to update any forward-looking statements. . Valve Disease. Pathology . Evidence for superiority of repair. Posterior Leaflet Posterior Leaflet Posterior Leaflet. Anterior Leaflet Cusp Anterolateral Scallop (P1) Middle Scallop (P2) Commissural Scallop (P3). Incidence of Mitral Valve Peravalvular Leak. Reported frequency of 1.2-12.5% after mitral valve replacement . Presenting symptoms. 73.3% heart failure. 16.2 % hemolysis. 10.3%no symptoms. Surgical results. Structure & Function. David J McCormack . BSc(Hons) MBBS . MFSTEd. . FRCSEd. (. CTh. ) FRCS (. CTh. ) . Consultant Surgeon . . Waikato Cardiothoracic Unit . Topics to be covered…. Location of the mitral valve . A Focused Review. David M. Harris MD, FASE, FACC. Disclosures- None. Goals. Review the physical examine finding of mitral . valvular. disease.. Learn the evaluation and treatment of mitral . valvular. To Treat or Not to . Treat, That . is The Question. **NAME**, DVM, DACVIM-Cardiology. **DATE**. William . Shakespeare’s . “. The . Tragedie. of Mitral. ”. To treat or not to treat: that is the question:. Overview. Rheumatic Heart Disease. Mitral Stenosis (. MS. ). Mitral Regurgitation . (. MR. ). Rheumatic Heart Disease. Rheumatic fever is an inflammatory disease that may develop after an infection with group of . 436 - 438 , May 2022 International Journal of Research Publication and Reviews Journal homepage: www.ijrpr.com ISSN 2582 - 7421 BARLOW’S SYNDROME: A CASE STUDY * Monika Tomar , M r s . Uma. M 2 , Definition Mitral valve prolapse is a heart problem in which the valve that separates the upper and lower chambers of the left side of the heart does not close properly. Alternative Names Barlow sy Temple Heart & Vascular Institute • Temple Health age 1 ABOUT MITRAL VALVE DISEASEThe mitral valve controls blood ow inside the heart. When working properly, this one-way valve opens to allo Temple Heart & Vascular Institute • Temple Health age 1 ABOUT MITRAL VALVE DISEASEThe mitral valve controls blood ow inside the heart. When working properly, this one-way valve opens to allo with signi cant functional mitral regurgitation who are not candidates for cardiac surgery.At The Mount Sinai Hospital, we employ a variety of sophisticated imaging techniques to select patients heart . valve prosthesis in a multicenter study on patients undergoing open heart valve surgery . Principal investigator:. Dr. Gholamreza Omrani. F. reely . floating valve . leaflets, CardiaMed. Rationale.